STAT3 and pancreatic neoplasm: Moreover, STAT3 inhibitors, such as the small-molecule inhibitor BBI-608 and monoclonal antibody SBT-100 have obtained orphan drug identification in pancreatic cancer and are undergoing clinical phase ΙΙΙ and Ι study, respectively.